LY3841136 sodium

LY3841136 sodium is an orally bioavailable small molecule agonist of the GDNF family receptor alpha-like (GFRAL), which is the specific receptor for Growth Differentiation Factor 15 (GDF15). Developed by Eli Lilly & Co., this compound is being investigated for the treatment of obesity, overweight, and knee osteoarthritis. GDF15 is a stress-induced hormone that signals through GFRAL in the hindbrain to regulate energy homeostasis, primarily by reducing food intake and promoting weight loss. By pharmacologically mimicking the effects of GDF15, LY3841136 sodium aims to provide a metabolic approach to weight management and potentially address the metabolic or inflammatory drivers of osteoarthritis. Unlike many other GDF15-based therapies that are biologics requiring injection, LY3841136 is notable for its small molecule modality and oral administration.